Singh RP, et al. (2009) Silibinin suppresses growth of human prostate carcinoma PC-3 orthotopic xenograft via activation of extracellular signal-regulated kinase 1/2 and inhibition of signal transducers and activators of transcription signaling. Clin Cancer Res 15, 613-21 19147767

This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.

Information from this record has been curated, but not yet edited in PhosphoSitePlus® and may be incomplete.

Click on the protein name to open the protein page, and on the RSD number to open the site page.

Download

S473-p - Akt1 (human) ▲

Modsite: RPHFPQFsysAsGtA SwissProt Entrez-Gene Orthologous residues Akt1 (human): S473‑p, Akt1 iso2 (human): S411‑p, Akt1 (mouse): S473‑p, Akt1 (rat): S473‑p, Akt1 (fruit fly): S586‑p, Akt1 (cow): S473‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Disease tissue studied:  prostate cancer Relevant cell lines - cell types - tissues:  PC3 (prostate cell) Cellular systems studied:  cell lines Species studied:  human, mouse Comments:  tumor xenograft model Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes silibinin inhibit treatment-induced increase

T202-p - ERK1 (human) ▲

Modsite: HDHtGFLtEyVAtRW SwissProt Entrez-Gene Orthologous residues ERK1 (human): T202‑p, ERK1 iso2 (human): T202‑p, ERK1 iso3 (human): T202‑p, ERK1 (mouse): T203‑p, ERK1 (rat): T203‑p, ERK1 (hamster): T192‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Disease tissue studied:  prostate cancer Relevant cell lines - cell types - tissues:  PC3 (prostate cell) Cellular systems studied:  cell lines Species studied:  human, mouse Comments:  tumor xenograft model Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes silibinin increase

Y204-p - ERK1 (human) ▲

Modsite: HtGFLtEyVAtRWyr SwissProt Entrez-Gene Orthologous residues ERK1 (human): Y204‑p, ERK1 iso2 (human): Y204‑p, ERK1 iso3 (human): Y204‑p, ERK1 (mouse): Y205‑p, ERK1 (rat): Y205‑p, ERK1 (hamster): Y194‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Disease tissue studied:  prostate cancer Relevant cell lines - cell types - tissues:  PC3 (prostate cell) Cellular systems studied:  cell lines Species studied:  human, mouse Comments:  tumor xenograft model Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes silibinin increase

T185-p - ERK2 (human) ▲

Modsite: HDHtGFLtEyVAtRW SwissProt Entrez-Gene Orthologous residues ERK2 (human): T185‑p, ERK2 (mouse): T183‑p, ERK2 (rat): T183‑p, ERK2 (chicken): T193‑p, ERK2 (cow): T185‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Disease tissue studied:  prostate cancer Relevant cell lines - cell types - tissues:  PC3 (prostate cell) Cellular systems studied:  cell lines Species studied:  human, mouse Comments:  tumor xenograft model Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes silibinin increase

Y187-p - ERK2 (human) ▲

Modsite: HtGFLtEyVAtRWyr SwissProt Entrez-Gene Orthologous residues ERK2 (human): Y187‑p, ERK2 (mouse): Y185‑p, ERK2 (rat): Y185‑p, ERK2 (chicken): Y195‑p, ERK2 (cow): Y187‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Disease tissue studied:  prostate cancer Relevant cell lines - cell types - tissues:  PC3 (prostate cell) Cellular systems studied:  cell lines Species studied:  human, mouse Comments:  tumor xenograft model Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes silibinin increase

T183-p - JNK1 (human) ▲

Modsite: AGtsFMMtPyVVtRY SwissProt Entrez-Gene Orthologous residues JNK1 (human): T183‑p, JNK1 iso2 (human): T183‑p, JNK1 iso3 (human): T183‑p, JNK1 (mouse): T183‑p, JNK1 (rat): T183‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Disease tissue studied:  prostate cancer Relevant cell lines - cell types - tissues:  PC3 (prostate cell) Cellular systems studied:  cell lines Species studied:  human, mouse Comments:  tumor xenograft model

Y185-p - JNK1 (human) ▲

Modsite: tsFMMtPyVVtRYYR SwissProt Entrez-Gene Orthologous residues JNK1 (human): Y185‑p, JNK1 iso2 (human): Y185‑p, JNK1 iso3 (human): Y185‑p, JNK1 (mouse): Y185‑p, JNK1 (rat): Y185‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Disease tissue studied:  prostate cancer Relevant cell lines - cell types - tissues:  PC3 (prostate cell) Cellular systems studied:  cell lines Species studied:  human, mouse Comments:  tumor xenograft model

T183-p - JNK2 (human) ▲

Modsite: ACtNFMMtPyVVtRY SwissProt Entrez-Gene Orthologous residues JNK2 (human): T183‑p, JNK2 iso2 (human): T183‑p, JNK2 iso3 (human): T183‑p, JNK2 (mouse): T183‑p, JNK2 iso4 (mouse): T183‑p, JNK2 (rat): T183‑p, JNK2 iso2 (rat): T183‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Disease tissue studied:  prostate cancer Relevant cell lines - cell types - tissues:  PC3 (prostate cell) Cellular systems studied:  cell lines Species studied:  human, mouse Comments:  tumor xenograft model Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes silibinin inhibit treatment-induced increase

Y185-p - JNK2 (human) ▲

Modsite: tNFMMtPyVVtRYYR SwissProt Entrez-Gene Orthologous residues JNK2 (human): Y185‑p, JNK2 iso2 (human): Y185‑p, JNK2 iso3 (human): Y185‑p, JNK2 (mouse): Y185‑p, JNK2 iso4 (mouse): Y185‑p, JNK2 (rat): Y185‑p, JNK2 iso2 (rat): Y185‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Disease tissue studied:  prostate cancer Relevant cell lines - cell types - tissues:  PC3 (prostate cell) Cellular systems studied:  cell lines Species studied:  human, mouse Comments:  tumor xenograft model Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes silibinin inhibit treatment-induced increase

S218-p - MEK1 (human) ▲

Modsite: VsGQLIDsMANsFVG SwissProt Entrez-Gene Orthologous residues MEK1 (human): S218‑p, MEK1 iso2 (human): S192‑p, MEK1 (mouse): S218‑p, MEK1 (rat): S218‑p, MEK1 (rabbit): S218‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Disease tissue studied:  prostate cancer Relevant cell lines - cell types - tissues:  PC3 (prostate cell) Cellular systems studied:  cell lines Species studied:  human, mouse Comments:  tumor xenograft model Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes silibinin inhibit treatment-induced increase

S222-p - MEK1 (human) ▲

Modsite: LIDsMANsFVGtRSY SwissProt Entrez-Gene Orthologous residues MEK1 (human): S222‑p, MEK1 iso2 (human): S196‑p, MEK1 (mouse): S222‑p, MEK1 (rat): S222‑p, MEK1 (rabbit): S222‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Disease tissue studied:  prostate cancer Relevant cell lines - cell types - tissues:  PC3 (prostate cell) Cellular systems studied:  cell lines Species studied:  human, mouse Comments:  tumor xenograft model Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes silibinin inhibit treatment-induced increase

T180-p - P38A (human) ▲

Modsite: RHtDDEMtGyVAtRW SwissProt Entrez-Gene Orthologous residues P38A (human): T180‑p, P38A iso2 (human): T180‑p, P38A (mouse): T180‑p, P38A iso3 (mouse): T180‑p, P38A (rat): T180‑p, P38A (salmonid): T181‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Disease tissue studied:  prostate cancer Relevant cell lines - cell types - tissues:  PC3 (prostate cell) Cellular systems studied:  cell lines Species studied:  human, mouse Comments:  tumor xenograft model Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes silibinin increase silibinin inhibit treatment-induced increase

Y182-p - P38A (human) ▲

Modsite: tDDEMtGyVAtRWYR SwissProt Entrez-Gene Orthologous residues P38A (human): Y182‑p, P38A iso2 (human): Y182‑p, P38A (mouse): Y182‑p, P38A iso3 (mouse): Y182‑p, P38A (rat): Y182‑p, P38A (salmonid): Y183‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Disease tissue studied:  prostate cancer Relevant cell lines - cell types - tissues:  PC3 (prostate cell) Cellular systems studied:  cell lines Species studied:  human, mouse Comments:  tumor xenograft model Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes silibinin increase silibinin inhibit treatment-induced increase

Y701-p - STAT1 (human) ▲

Modsite: DGPkGtGyIktELIs SwissProt Entrez-Gene Orthologous residues STAT1 (human): Y701‑p, STAT1 iso2 (human): Y701‑p, STAT1 (mouse): Y701‑p, STAT1 (rat): Y701‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Disease tissue studied:  prostate cancer Relevant cell lines - cell types - tissues:  PC3 (prostate cell) Cellular systems studied:  cell lines Species studied:  human, mouse Comments:  tumor xenograft model Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes silibinin inhibit treatment-induced increase

S727-p - STAT1 (human) ▲

Modsite: TDNLLPMsPEEFDEV SwissProt Entrez-Gene Orthologous residues STAT1 (human): S727‑p, STAT1 iso2 (human): ‑, STAT1 (mouse): S727‑p, STAT1 (rat): S727‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Disease tissue studied:  prostate cancer Relevant cell lines - cell types - tissues:  PC3 (prostate cell) Cellular systems studied:  cell lines Species studied:  human, mouse Comments:  tumor xenograft model Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes silibinin inhibit treatment-induced increase

Y705-p - STAT3 (human) ▲

Modsite: DPGsAAPyLktKFIC SwissProt Entrez-Gene Orthologous residues STAT3 (human): Y705‑p, STAT3 iso2 (human): Y704‑p, STAT3 iso3 (human): Y705‑p, STAT3 (mouse): Y705‑p, STAT3 iso2 (mouse): Y705‑p, STAT3 iso3 (mouse): Y704‑p, STAT3 (rat): Y705‑p, STAT3 (cow): Y705‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Disease tissue studied:  prostate cancer Relevant cell lines - cell types - tissues:  PC3 (prostate cell) Cellular systems studied:  cell lines Species studied:  human, mouse Comments:  tumor xenograft model Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes silibinin inhibit treatment-induced increase

S727-p - STAT3 (human) ▲

Modsite: NtIDLPMsPrTLDSL SwissProt Entrez-Gene Orthologous residues STAT3 (human): S727‑p, STAT3 iso2 (human): S726‑p, STAT3 iso3 (human): ‑, STAT3 (mouse): S727‑p, STAT3 iso2 (mouse): ‑, STAT3 iso3 (mouse): S726‑p, STAT3 (rat): S727‑p, STAT3 (cow): S727‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Disease tissue studied:  prostate cancer Relevant cell lines - cell types - tissues:  PC3 (prostate cell) Cellular systems studied:  cell lines Species studied:  human, mouse Comments:  tumor xenograft model Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes silibinin inhibit treatment-induced increase

Y694-p - STAT5A (human) ▲

Modsite: LAkAVDGyVkPQIkQ SwissProt Entrez-Gene Orthologous residues STAT5A (human): Y694‑p, STAT5A (mouse): Y694‑p, STAT5A iso2 (mouse): ‑, STAT5A (rat): Y694‑p, STAT5A (fruit fly): ‑, STAT5A (sheep): Y694‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Disease tissue studied:  prostate cancer Relevant cell lines - cell types - tissues:  PC3 (prostate cell) Cellular systems studied:  cell lines Species studied:  human, mouse Comments:  tumor xenograft model Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes silibinin inhibit treatment-induced increase